Pasar al contenido principal

IMPACTO CLINICO DE LA HETEROGENEIDAD GENOMICA Y EVOLUCION CLONAL EN NEOPLASIAS LINFOIDES B. DEFINICION DE NUEVOS MODELOS DIAGNOSTICOS Y PRONOSTICOS.

SAF2015-64885-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms

  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Demajo, Santiago
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Pinyol, Magda
  • García, Noelia
  • Capdevila, Cristina
  • Clot, Guillem|||0000-0003-2588-7413
  • Suárez-Cisneros, Helena|||0000-0003-4636-2106
  • Shimada, Mariko
  • Karube, Ken
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Colomer, Dolors|||0000-0001-7486-8484
  • Beà, Sílvia
  • Martin-Subero, Jose Ignacio|||0000-0001-8809-5195
  • Campo, Elias|||0000-0001-9850-9793
  • Jares, Pedro
Cyclin D1 is an oncogene frequently overexpressed in human cancers that has a dual function as cell cycle and transcriptional regulator, although the latter is widely unexplored. Here, we investigated the transcriptional role of cyclin D1 in lymphoid tumor cells with cyclin D1 oncogenic overexpression. Cyclin D1 showed widespread binding to the promoters of most actively transcribed genes, and the promoter occupancy positively correlated with the transcriptional output of targeted genes. Despite this association, the overexpression of cyclin D1 in lymphoid cells led to a global transcriptional downmodulation that was proportional to cyclin D1 levels. This cyclin D1-dependent global transcriptional downregulation was associated with a reduced nascent transcription and an accumulation of promoter-proximal paused RNA polymerase II (Pol II) that colocalized with cyclin D1. Concordantly, cyclin D1 overexpression promoted an increase in the Poll II pausing index. This transcriptional impairment seems to be mediated by the interaction of cyclin D1 with the transcription machinery. In addition, cyclin D1 overexpression sensitized cells to transcription inhibitors, revealing a synthetic lethality interaction that was also observed in primary mantle cell lymphoma cases. This finding of global transcriptional dysregulation expands the known functions of oncogenic cyclin D1 and suggests the therapeutic potential of targeting the transcriptional machinery in cyclin D1-overexpressing tumors.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

  • Vilarrasa-Blasi, Roser
  • Soler-Vila, Paula
  • Verdaguer-Dot, Núria
  • Russiñol, Núria
  • Di Stefano, Marco
  • Chapaprieta, Vicente
  • Clot, Guillem
  • Farabella, Irene
  • Cuscó Pons, Pol, 1987-
  • Kulis, Marta
  • Agirre, Xabier
  • Prosper, Felipe
  • Beekman, Renée
  • Beà, Sílvia
  • Colomer Pujol, Dolors
  • Stunnenberg, Hendrik G.
  • Gut, Ivo Glynne
  • Campo, Elias
  • Martí Renom, Marc A.
  • Martin-Subero, José Ignacio
To investigate the three-dimensional (3D) genome architecture across normal B cell differentiation and in neoplastic cells from different subtypes of chronic lymphocytic leukemia and mantle cell lymphoma patients, here we integrate in situ Hi-C and nine additional omics layers. Beyond conventional active (A) and inactive (B) compartments, we uncover a highly-dynamic intermediate compartment enriched in poised and polycomb-repressed chromatin. During B cell development, 28% of the compartments change, mostly involving a widespread chromatin activation from naive to germinal center B cells and a reversal to the naive state upon further maturation into memory B cells. B cell neoplasms are characterized by both entity and subtype-specific alterations in 3D genome organization, including large chromatin blocks spanning key disease-specific genes. This study indicates that 3D genome interactions are extensively modulated during normal B cell differentiation and that the genome of B cell neoplasias acquires a tumor-specific 3D genome architecture., This research was funded by the European Union’s Seventh Framework Programme through the Blueprint Consortium (grant agreement 282510), the World Wide Cancer Research Foundation Grant No. 16-1285 (to J.I.M.-S.), the ERC (grant agreement 609989 to M.A.M.-R.), European Union’s Horizon 2020 research and innovation programme (grant agreement 676556 to M.A.M.-R.). We also knowledge the support of Spanish Ministerio de Ciencia, Innovación y Universidades through SAF2012-31138 and SAF2017-86126-R to J.I.M.-S., SAF2015-64885-R to E.C., BFU2017-85926-P to M.A.M.-R. and PMP15/00007 to E.C. which is part of Plan Nacional de I + D + I and co-financed by the ISCIII-Sub-Directorate General for Evaluation and the European Regional Development Fund (FEDER-“Una manera de Hacer Europa”) (to E.C.), the International Cancer Genome Consortium (Chronic Lymphocytic Leukemia Genome consortium to E.C.), La Caixa Foundation (CLLEvolution-HE17-00221, to E.C.). Furthermore, the authors would like to thank the support of the Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-736 (to J.I.M.-S.), 2017-SGR-1142 (to E.C.) and 2017-SGR-468 (to E.C.), the Accelerator award CRUK/AIRC/AECC joint funder-partnership, the CERCA Programme/Generalitat de Catalunya and CIBERONC (CB16/12/00225, CB16/12/00334, and CB16/12/00489). R.V.-B. (BES-2013-064328) and P.S.-V. (BES-2014-070327) were supported by a predoctoral FPI Fellowship from the Spanish Government. CRG acknowledges support from ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208 and the CERCA Programme/Generalitat de Catalunya as well as support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the EMBL partnership, the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement, and the Cofinancing with funds from the European Regional Development Fund (ERDF) by the Spanish Ministry of Science and Innovation coresponding to the Programa Opertaivo FEDER Plurirregional de España (POPE) 2014-2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the programa Operatiu FEDER Catalunya 2014-2020
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, Kennosuke
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Salar, Antonio
  • Colomo Saperas, Luis Alberto
  • López Bigas, Núria
  • Miyoshi, Hiroaki
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies., This study was supported by the Ministerio de Economía y Competitividad, Grant No. SAF2015-64885- R (to EC), Generalitat de Catalunya Suport Grups de Recerca AGAUR 2014-SGR-795 (to EC), Instituto de Salud Carlos III, Spanish Ministry of Health, PI12/01536 (to AL-G) and PI16/00420 (to AL-G), the Red Temática de Investigación Cooperativa en Cáncer (RTICC) grant RD12/0036/0036 (to EC), RD12/0036/0023 (to AL-G), RD12/0036/0069 (to MA), BIO/SA78/15 (to MA) and the European Regional Development Fund 'Una manera de fer Europa', CERCA Programme/Generalitat de Catalunya. EC is an Academia Researcher of the 'Institució Catalana de Recerca i Estudis Avançats' (ICREA) of the Generalitat de Catalunya. KK has received a research fellowship from the Uehara Memorial Foundation (Japan). DT is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ and SAF2015-74072-JIN. CR-P is supported by an FPI fellowship. ID is supported by 'Josep Font' grant from Hospital Clinic. This work was also supported by La Fundació la Marató de TV3 and EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics), and the European Research Council (consolidator grant 682398) (to NL-B).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

  • Vilarrasa-Blasi, Roser
  • Soler-Vila, Paula
  • Verdaguer-Dot, Núria
  • Russiñol, Núria
  • Di Stefano, Marco
  • Chapaprieta, Vicente
  • Clot, Guillem
  • Farabella, Irene
  • Cuscó Pons, Pol, 1987-
  • Kulis, Marta
  • Agirre, Xabier
  • Prosper, Felipe
  • Beekman, Renée
  • Beà, Sílvia
  • Colomer Pujol, Dolors
  • Stunnenberg, Hendrik G.
  • Gut, Ivo Glynne
  • Campo, Elias
  • Martí Renom, Marc A.
  • Martin-Subero, José Ignacio
To investigate the three-dimensional (3D) genome architecture across normal B cell differentiation and in neoplastic cells from different subtypes of chronic lymphocytic leukemia and mantle cell lymphoma patients, here we integrate in situ Hi-C and nine additional omics layers. Beyond conventional active (A) and inactive (B) compartments, we uncover a highly-dynamic intermediate compartment enriched in poised and polycomb-repressed chromatin. During B cell development, 28% of the compartments change, mostly involving a widespread chromatin activation from naive to germinal center B cells and a reversal to the naive state upon further maturation into memory B cells. B cell neoplasms are characterized by both entity and subtype-specific alterations in 3D genome organization, including large chromatin blocks spanning key disease-specific genes. This study indicates that 3D genome interactions are extensively modulated during normal B cell differentiation and that the genome of B cell neoplasias acquires a tumor-specific 3D genome architecture., This research was funded by the European Union’s Seventh Framework Programme through the Blueprint Consortium (grant agreement 282510), the World Wide Cancer Research Foundation Grant No. 16-1285 (to J.I.M.-S.), the ERC (grant agreement 609989 to M.A.M.-R.), European Union’s Horizon 2020 research and innovation programme (grant agreement 676556 to M.A.M.-R.). We also knowledge the support of Spanish Ministerio de Ciencia, Innovación y Universidades through SAF2012-31138 and SAF2017-86126-R to J.I.M.-S., SAF2015-64885-R to E.C., BFU2017-85926-P to M.A.M.-R. and PMP15/00007 to E.C. which is part of Plan Nacional de I + D + I and co-financed by the ISCIII-Sub-Directorate General for Evaluation and the European Regional Development Fund (FEDER-“Una manera de Hacer Europa”) (to E.C.), the International Cancer Genome Consortium (Chronic Lymphocytic Leukemia Genome consortium to E.C.), La Caixa Foundation (CLLEvolution-HE17-00221, to E.C.). Furthermore, the authors would like to thank the support of the Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-736 (to J.I.M.-S.), 2017-SGR-1142 (to E.C.) and 2017-SGR-468 (to E.C.), the Accelerator award CRUK/AIRC/AECC joint funder-partnership, the CERCA Programme/Generalitat de Catalunya and CIBERONC (CB16/12/00225, CB16/12/00334, and CB16/12/00489). R.V.-B. (BES-2013-064328) and P.S.-V. (BES-2014-070327) were supported by a predoctoral FPI Fellowship from the Spanish Government. CRG acknowledges support from ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208 and the CERCA Programme/Generalitat de Catalunya as well as support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the EMBL partnership, the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement, and the Cofinancing with funds from the European Regional Development Fund (ERDF) by the Spanish Ministry of Science and Innovation coresponding to the Programa Opertaivo FEDER Plurirregional de España (POPE) 2014-2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the programa Operatiu FEDER Catalunya 2014-2020
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, Kennosuke
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Salar, Antonio
  • Colomo Saperas, Luis Alberto
  • López Bigas, Núria
  • Miyoshi, Hiroaki
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies., This study was supported by the Ministerio de Economía y Competitividad, Grant No. SAF2015-64885- R (to EC), Generalitat de Catalunya Suport Grups de Recerca AGAUR 2014-SGR-795 (to EC), Instituto de Salud Carlos III, Spanish Ministry of Health, PI12/01536 (to AL-G) and PI16/00420 (to AL-G), the Red Temática de Investigación Cooperativa en Cáncer (RTICC) grant RD12/0036/0036 (to EC), RD12/0036/0023 (to AL-G), RD12/0036/0069 (to MA), BIO/SA78/15 (to MA) and the European Regional Development Fund 'Una manera de fer Europa', CERCA Programme/Generalitat de Catalunya. EC is an Academia Researcher of the 'Institució Catalana de Recerca i Estudis Avançats' (ICREA) of the Generalitat de Catalunya. KK has received a research fellowship from the Uehara Memorial Foundation (Japan). DT is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ and SAF2015-74072-JIN. CR-P is supported by an FPI fellowship. ID is supported by 'Josep Font' grant from Hospital Clinic. This work was also supported by La Fundació la Marató de TV3 and EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics), and the European Research Council (consolidator grant 682398) (to NL-B).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, K.
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Dlouhy, Iván|||0000-0003-3066-4732
  • Jares, Pedro
  • Martín-García, David|||0000-0002-0289-5915
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Ordóñez, G.R.
  • Rovira, Jordi|||0000-0001-8737-5005
  • Clot, Guillem|||0000-0003-2588-7413
  • Royo, C.
  • Navarro, Alba|||0000-0002-4041-0974
  • González Farré, Blanca|||0000-0002-1796-7248
  • Vaghefi, A.
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Rubio-Perez, C.
  • Tamborero, David
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Gonzalez-Barca, E.
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Miyoshi, H.
  • Ohshima, K.
  • Miyawaki, K.
  • Kato, K.
  • Akashi, K.
  • Mozos, Ana|||0000-0002-3350-1827
  • Colomo, Luis|||0000-0001-5236-5085
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Valera, A.
  • Carrió, A.
  • Costa, Dolors|||0000-0002-8276-3292
  • Lopez-Bigas, N.
  • Schmitz, R.
  • Staudt, L.M.
  • Salaverria, I.
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Campo, Elias|||0000-0001-9850-9793
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies.